Lee Sung-Bum, Yoo Byungwook, Baeg Chaemin, Yun Jiae, Ryu Dong-Wook, Kim Gyungcheon, Kim Seongok, Shin Hakdong, Lee Ju Hee
Department of Family Medicine, Soonchunhyang University Bucheon Hospital, Bucheon 22972, Republic of Korea.
Department of Family Medicine, Soonchunhyang University Seoul Hospital, Seoul 04401, Republic of Korea.
Nutrients. 2025 Mar 28;17(7):1191. doi: 10.3390/nu17071191.
This study aims to evaluate the efficacy and safety of probiotics for body fat reduction in obese individuals.
A total of 106 participants with a body mass index between 25 and 30 kg/m were randomly assigned to either the experimental group treating with LMT1-48 or the placebo group in the placebo-controlled clinical trial. Body composition was assessed by dual-energy X-ray absorptiometry and computed tomography. Fecal samples between the groups were contrasted via DNA sequencing for evaluation of the microbiota and its diversity.
After 12 weeks of follow-up period, the body fat mass decreased significantly, from 30.0 ± 4.4 to 28.3 ± 4.1 kg in the experimental group ( = 0.009). The percentage of body fat in the two groups showed a similar trend ( = 0.004).
LMT1-48 also positively influenced the microbial taxa linked to obesity analyzed by gut microbiome sequencing. LMT1-48 is a safe and collaborative agent to reduce obesity.
本研究旨在评估益生菌对肥胖个体减脂的有效性和安全性。
在这项安慰剂对照临床试验中，将106名体重指数在25至30kg/m之间的参与者随机分为接受LMT1 - 48治疗的实验组或安慰剂组。通过双能X线吸收法和计算机断层扫描评估身体成分。通过DNA测序对比两组之间的粪便样本，以评估微生物群及其多样性。
经过12周的随访期，实验组的体脂量显著下降，从30.0±4.4kg降至28.3±4.1kg（P = 0.009）。两组的体脂百分比呈现相似趋势（P = 0.004）。
通过肠道微生物组测序分析，LMT1 - 48对与肥胖相关的微生物分类群也有积极影响。LMT1 - 48是一种安全且有助于减轻肥胖的制剂。
